Le Lézard
Classified in: Health
Subject: SVY

International Patent Reviews Releases Study on Sun Pharmaceuticals' LEVULAN® KERASTICK® patent


DALLAS, July 26, 2021 /PRNewswire/ -- Today, International Patent Reviews, LLC (IPR) released a study on Sun Pharmaceuticals' U.S. Patent No. 10,357,567 directed to technology around their LEVULAN® KERASTICK®. A copy of the study can be found at IPR's website.

IPR is focused on identifying patents filed by pharmaceutical companies that do not represent novel inventions suitable for protection. Dr. R. L. Smith of IPR stated that "the patent system was designed to be entrusted to authentic inventors and legitimate drug research and development organizations. However, many pharmaceutical filings are purposefully structured to artificially extend the reach of protection afforded by our patent system." Dr. Smith went on to say that "this practice has the effect of raising the costs of drugs on those that need them."

IPR has developed a comprehensive and multifaceted process for identifying pharmaceutical patent filings that have taken advantage of the patent system.  Once a patent has been identified, IPR makes every effort to expose it as neither unique nor useful. Dr. Smith said, "While our team generates some of the best and most comprehensive studies available in the industry, our work can only improve with further public scrutiny and crowdsourcing, and we hope that the information can be used for defeating these weak patents and to help control the runaway costs of branded pharmaceuticals."

The first patent for LEVULAN® KERASTICK® was issued in January of 1992. The '567 patent has an expected expiration date reaching into January of 2038. This is a span of over 46 years from the time of issuance of the first patent to the expiration of the latest. Dr. Smith commented that "the '567 seems to be an inequitable extension of valid patent rights granted by the U.S. government. It looks as if the protection has been speciously extended by a process we refer to as 'ever-greening'. That is, making small, rather insignificant changes to the process in order to gain a new patent with a longer time for exclusivity."

IPR hopes that interested parties, competitive pharmaceutical companies, and other stake holders will use this freely available information to help bring down the cost of this drug for patients, hospitals, and caregivers.

 

SOURCE International Patent Reviews, LLC


These press releases may also interest you

at 04:28
GymNation, the homegrown UAE fitness brand, has today announced that due to unprecedented growth, it is reaching capacity across its 12 UAE gym locations and diversifying into a new market, brewing up a storm with the launch of its first-ever branded...

at 04:00
Cancer spreads from its primary tumor to other parts of the body via blood or the lymphatic system in a process termed 'metastasis'. This usually represents an advanced stage in the disease's progression and tends to be fatal. Therefore, preventing...

at 03:30
Vicore Pharma Holding (STO:VICO)Sessions at ATS to include an oral late-breaking presentation of the final results from the Phase 2a AIR trial of buloxibutid (C21) in IPFAdditional presentations include preclinical and translational data reflecting...

at 03:13
Orexo's Annual and Sustainability Report for 2023 has been published and can be downloaded at, www.orexo.com. The Swedish version of the Report is also available on the company's website in European Single Electronic Format (ESEF). A PDF version is...

at 03:05
Surge has just closed its second round of funding, raising ?7.5 million. The round was led by Eurazeo with the participation of Kima, Teampact, and MH Innov', as well as the support of historical funds Boutique Venture, HCVC, and 50 Partners Santé....

at 03:00
CSL Vifor is pleased that its partner Akebia Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Vafseo (vadadustat) tablets for the treatment of anemia due to chronic kidney disease (CKD) in adults who...



News published on and distributed by: